Clinical Trial Update: Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Epstein-Barr Virus-Specific Immunotherapy for nasopharyngeal carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Epstein-Barr Virus-Specific Immunotherapy

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Nasopharyngeal Carcinoma | Phase 1 | Status: COMPLETED